| Literature DB >> 35744998 |
Anna Helena Mazurek1, Łukasz Szeleszczuk2.
Abstract
This article aims to review the application of various quantum chemical methods (semi-empirical, density functional theory (DFT), second order Møller-Plesset perturbation theory (MP2)) in the studies of cyclodextrin host-guest complexes. The details of applied approaches such as functionals, basis sets, dispersion corrections or solvent treatment methods are analyzed, pointing to the best possible options for such theoretical studies. Apart from reviewing the ways that the computations are usually performed, the reasons for such studies are presented and discussed. The successful applications of theoretical calculations are not limited to the determination of stable conformations but also include the prediction of thermodynamic properties as well as UV-Vis, IR, and NMR spectra. It has been shown that quantum chemical calculations, when applied to the studies of CD complexes, can provide results unobtainable by any other methods, both experimental and computational.Entities:
Keywords: CD complexes; DFT; QC; cyclodextrin; density functional theory; host–guest complexes; quantum chemistry
Mesh:
Substances:
Year: 2022 PMID: 35744998 PMCID: PMC9229288 DOI: 10.3390/molecules27123874
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Number of the search results for the ‘cyclodextrin AND DFT’ phrase in the Web of Science. Each column shows the number of articles in the given year and all years before. For example, the column entitled ‘2010’ depicts the number of articles published in the period 2000–2010, including 2010.
Figure 2Changes in the number of articles published on the topic of cyclodextrin and either different semi-empirical or DFT methods over the years.
Selected articles published in the years 2015–2022 on the application of DFT methods for systems that included CD. The functional and basis set information concerns CD complexes, not guests. Abbreviations used in table: DM-CD (2,6-dimethylo-CD), TM-CD (trimetylo-CD), per-M-CD (permethylated-CD), geo. opt. (geometry optimization), SP (single point calculations), NMR (1H NMR spectra simulation), NBO (Natural Bond Orbitals), BJ (Becke Johnson damping function),TD (thermodynamics calculations), n.i.p. (no information provided). In the case where the DFT application in the published research occurs only as an ONIOM component, the article has not been included in the table. The ONIOM approach along with the examples has been described in Section 2.2.
| No. | CD | Guest | Functional | Basis Set | Environment | DFT Application | Ref. |
|---|---|---|---|---|---|---|---|
|
| |||||||
| 1 | β | (s)-2-Isopropyl-1-(o-nitrophenyl) Sulfonyl) Aziridine | B3LYP, WB97X-D, B97D3 | 6-31G(d) | gas, water | [ | |
| 2 | β | boron-based aromatic systems | BLYP-D3(BJ) | def2-SVP | vacuum, CPCM | geo. opt., natural bond orbital calculations (NBO), complexation energy | [ |
| 3 | α, β, γ | alprazolam | B3LYP, M06L | def-TZVP | vacuum | geo. opt. in gas, NMR spectra | [ |
| 4 | β | lenalidomide | B3LYP, M06-2X | 6-31G(d,p) | PCM | [ | |
| 5 | β | dexamethasone | BLYP-D4 | def2-TZVP | gas, water | geo. opt., complexation energy | [ |
| 6 | β | 2,2′-Bipyridine | B3LYP, wB97XD | 6-31G(d) | PCM (eight solvents) | geo. opt., UV–Vis spectrum, HOMO-LUMO | [ |
| 7 | β | 2,2′-Dipyridylamine | B3LYP | 6-311++G(d,p) | PCM | [ | |
| 8 | vardenafil hydrochloride | B3LYP | 6-311G(2d,2p) | vacuum | geo. opt., FT-IR | [ | |
| 9 | amino-CD | doxorubicin | B3LYP | 6-31G | vacuum | geo. opt., complexation energy, HOMO-LUMO, dipole moment, chemical potential, electrophilicity | [ |
| 10 | β | 5-fluorouracil | B3LYP-D3 | 6-31+G(d,p) | vacuum, PCM | geo. opt., complexation energy, harmonic frequency calculations | [ |
| 11 | HP-β | 2-methyl mercapto phenothiazine | B97-D3, BP86-D3 | 6-31G(d,p) | gas, CPCM | geo. opt., vibrational spectra, NBO, QTAIM, HOMO-LUMO | [ |
| 12 | β | vemurafenib | ωB97XD | 6-31+G(d) | vacuum, PCM | Geo. opt., vibrational spectra, MD, NBO, TD, HOMO-LUMO | [ |
| 13 | β | procaine hydrochloride | B3LYP, M06-2X, WB97XD | 6-31G(d,p) | gas, PCM | Geo. opt., NBO | [ |
| 14 | β, SBE-β | fluorometholone, cholesterol | M06-2X | 6-31G** | PCM | Geo opt., interaction energy | [ |
| 15 | α, β, γ | chlordecone | M06-2X-D3 | 6-31G(d,p) | SMD | Geo. opt., QTAIM | [ |
| 16 | β, methyl-β | nicotine | M06-2X | 6-31G(d,p) | n.i.p. | Geo., opt., complexation enrgy | [ |
| 17 | β | 8-Anilinonaphthalene-1-sulfonate | B3LYP, M06-2X, WB97X-D | 6-31G(d) | gas, water | Geo. opt., interaction energy, NMR, TD, NBO | [ |
| 18 | β | benzocaine | B3LYP, CAM-B3LYP, M05-2X, M06-2X | 6-31G(d,p) | PCM | Geo. opt., QTAIM, NBO, NMR, HOMO-LUMO, TD | [ |
| 19 | β | aryl pentazole | M06-2X | 6-31+G(d,p) | PCM | Geo. opt. | [ |
| 20 | β | 2,4D, dicamba pesticides | PBE1PBE (PBE0), B97-D, M06-2X | 6-31G(d,p) | gas, SMD | Geo. opt. | [ |
| 21 | Monochlorotriazinyl-β | permethrin, cyppermethrin | BLYP (geo. opt.); BLYP-D3, B3LYP-D3, M06-2X-D3 (UV–Vis) | def2-SV(P) (geo. opt.); TZVP (UV–Vis) | COSMO | Geo. opt. | [ |
| 22 | β | dopamine | B3LYP, MPW1PW91, M05-2X, M06-2X, ωB97X-D | 3-21G* | CPCM | Geo. opt., complexation energy, QTAIM, NBO | [ |
| 23 | α | benzoate derivatives | M06L (geo. opt.); M06-2X//M06-L (SP) | 6-31+G(d,p) | gas | Geo. opt. | [ |
| 24 | α, β, γ | cholic, deoxycholic acid | B97-D, M06-2X, B3LYP | 6-31G(d) | PCM | Geo. opt., interaction energy | [ |
| 25 | α | benzoate derivatives | M06-2X//M06-L, M06-2X//BLYP, BLYP, M06-2X | 6-31+G(d,p) | gas | Geo. opt., interaction energy | [ |
| 26 | γ | cetirizine | B3LYP | def-TZVP | n.i.p. | Geo.opt., interaction energy, HOMO-LUMO, DOS, NMR | [ |
| 27 | succinyl-β | uranium | M06-2X | 6-31G(d,p) | SMD | Geo. opt. | [ |
| 28 | β-CD, DM -β | thymidine-carbonate | B3LYP-GD2 | 6-31G(d,p) | PCM | Geo. opt., complexation energy, TD, HOMO-LUMO, NMR | [ |
| 29 | β | glycyl-L-phenylalanine | B3LYP | 3-21G(d) | PCM | Geo. opt., interaction energy, HOMO-LUMO | [ |
| 30 | β | sodium salicylate | B3LYP | 6-31G(d) | gas, PCM | Geo. opt., solvation energy, relative stabilization energy, complexation energy, | [ |
| 31 | β | benzyl isothiocyanthe | B97-D3 | def2-SVP | vacuum | Geo. opt., complexation energy, HOMO-LUMO, NBO, NMR | [ |
| 32 | α | iodine solution | CAM-B3LYP | 6-31*G | PCM | Geo. opt., absorption spectra, HOMO-LUMO | [ |
| 33 | β | meta-aminophenol | M06-2X | 6-31G(d,p) | IEFPCM | Geo. opt., complexation energy, HOMO-LUMO, TD, NBO | [ |
| 35 | β | L-glutamine | B97-D3 | 6-31G(d) | n.i.p. | Geo. opt., complexation energy, TD, NBO, QTAIM | [ |
| 36 | β | R and S ibuprofen | M062X | 6-31G(d,p) (geo. opt.); 6-311++G(d,p) (SP) | gas, SMD | Geo. opt., solvation energy | [ |
| 37 | α, β | thioureides | B97-D3 | 6–31G(d,p) | Geo. opt., interaction energy | [ | |
| 38 | β | mepivacaine | B97-D3 | 6-31G(d,p) | gas, SMD | Geo. opt., interaction energy, TD | [ |
| 39 | β | L-metheonine | WB97-D3 | 6-31G(d) | PCM | geo. opt., interaction energy, QTAIM, TD, NMR | [ |
| 40 | β | prazosin, losartan | B3LYP | 6–311+G(d,p) | gas | Geo. opt. | [ |
| 41 | β | olsalazine | B3LYP, WB97-D3, CAM-B3LYP (UV-vis) | 6-31+G(d) | PCM | Geo. opt., ADMP | [ |
| 42 | β | aspirin | B3LYP-D3 | cc-pVDZ | gas | Geo. opt., qTAIM, NBO | [ |
| 43 | β | quinine | B3PW91 | 6-311++G(d,p) | PCM | Geo. opt. | [ |
| 44 | β | erlotinib | B3LYP | 6-31+G* | n.i.p. | Geo. opt., harmonic frequencies, HOMO-LUMO | [ |
| 45 | γ | rocuronium, vecuronium | B3LYP | 6–31+G(d,p) | n.i.p. | Geo. opt., NBO, HOMO-LUMO | [ |
| 46 | α, β, γ | cathinone | M05-2X | 6-31G(d) | gas, CPCM (water, chloroform, methanol) | Geo. opt., QTAIM, NBO, IR spectra, TD | [ |
| 47 | α | CO2 | B3LYP | G-31G* | PCM | NMR | [ |
| 48 | β | flutafemic acid | B3LYP, M05-2X | 6-31G(d) | vacuum, water | Geo. opt., complexation energy, TD, NMR | [ |
| 49 | 2-HP-β | Cu (II) and Fe (III) complexes of quercetin, morin, primuletin | B3LYP | 6-311++G** | n.i.p. | Geo. opt., complexation energy, HOMO-LUMO | [ |
| 50 | β | 6-thioguanine, 6-mercaptopurine | B3LYP | 6-31+g(d,p) | IEFPCM (DMSO) | Geo. opt., interaction energy, TD | [ |
| 51 | β | N-(2-chloroethyl),N -nitroso,N′,N′-dicyclohexylsulfamid | B3LYP | 6-31G(d) | PCM (DMSO) | Geo. opt., NBO, QTAIM | [ |
| 52 | β | benzaldehyde | B97-D | 6-31G(d,p) (geo. opt.); 6-311++G(2d,p) (SP) | gas, SMD | Geo. opt., interaction energy, TD | [ |
| 53 | α | chitibiose | M06-2X | 6-311++G** | n.i.p. | Geo. opt., NBO, QTAIM | [ |
| 54 | α | hydrated and nonhydrated IIA/IIB group metal cations | M06-2X | 6-31G(d,p) | gas, PCM | Geo. opt., interaction energy, TD | [ |
| 55 | β | nabumetone | WB97X-D, B97-D, B3LYP, M05-2X, M06-2X | 6-31G(d) | IEFPCM | Geo. opt., NBO, QTAIM | [ |
| 56 | β | propranolol | B3LYP, ωB97XB (ONIOM) | 6-31+G(d) | gas, IEFPCM, explicit solvent effect: explicit water molecules inside of the complex | Geo. opt., interaction energy, ADMP, TD | [ |
| 57 | functionalized CDs | 8-hydroxyquinoline ligands | B3LYP | 6-31G** | n.i.p. | Geo. opt. | [ |
| 58 | β | pentoxifilline | M06-2X | 6-31g(d,p) | gas | Geo. opt., NBO, HOMO-LUMO | [ |
| 59 | β | p-nitropenthyl acetate | B3LYP | 6-31G(d,p) | n.i.p. | Geo. opt., interaction energy, NBO, HOMO-LUMO | [ |
| 60 | β | norfloxacin | B97D (geo. opt.), B3LYP (SP, NMR) | 6-31G(d,p) | IEFPCM | Geo. opt., interaction and stabilization energy, NMR, TD | [ |
|
| |||||||
| 61 | β | paroxetine | B3LYP (geo. opt.); B97D (SP) | 6-31+G* for H, N, O and 4-31G for C | vacuum | Geo. opt., interaction energy, TD | [ |
| 62 | 2,6-DM-β | mianserin | B3LYP-GD2 (geo. opt.); M05-GD3, M06-GD3, M062X-GD3, ωB97XD, mPW1PW91, M11 (SP) | 6-31G(d,p) | PCM, vacuum | Geo. opt., interaction energy, NMR | [ |
| 63 | β | sertraline HCl, fluoxetine HCl | B3LYP | 6-31+G* for H, N, O and 4-31G for C | gas | Geo. opt., interaction energy | [ |
| 64 | β | protriptyline, maprotiline | B3LYP | 6-31+G* for H, N, O and 4-31G for C | vacuum | Geo. opt., interaction and stabilization energy | [ |
| 65 | β | clomipramine, doxepin | B3LYP | 31+G(d) for H, N, O, Cl, and 4-31G for C | gas | Geo. opt., interaction energy | [ |
| 66 | β | desipramine, imipramine | B3LYP | 6-31þG(d) for H, N, O and 4- 31G for C | gas, implicit solvent (water) | Geo. opt., interaction and stabilization energy | [ |
| 67 | β | amitryptyline, nortryptiline | n.i.p. | 6-31+G* for H, N, O, Cl and 4-31G for C | vacuum, SMD | Geo. opt., interaction and stabilization energy | [ |
|
| |||||||
| 68 | HP-β | thymoquinone | B3LYP-D2, B3LYP-D3 | 6-31G(d,p) | PCM | Geo. opt., NBO, QTAIM, HOMO-LUMO, NMR | [ |
| 69 | α | β-carotene | B3LYP | cc-pVDZ | vacuum | Geo. opt., interaction energy, Raman spectra | [ |
| 70 | γ | 3-hydroxyflavone | PBE0 | def2-SV | PCM | Geo. opt., HOMO-LUMO, IT spectra | [ |
| 71 | β | vanillina | B3LYP, ωB97xD, M06- 2X | 6-311G(d,p) | vacuum, CPCM | Geo. opt., interaction energy, NMR, HOMO-LUMO, NBO, QTAIM, UV–Vis | [ |
| 72 | β | alfa-terpineol | B3LYP (for UV–Vis), B3LYP/CAM, M062X, WB97-D3 | 6-311G(d,p) | vacuum, CPCM | Geo. opt., complexation energy, NBO, QTAIM, TD, UV-vis | [ |
| 73 | TM-β, β | naringenin | B3LYP, M06-2X, wB97X-D | 6-31G(d) | vacuum | Geo. opt., interaction energy, NBO, QTAIM, NMR, HOMO-LUMO | [ |
| 74 | 2,6-DMβ, 2HP-β, 2,6-DH-β, β | eucalyptol | M06-2X | 6-31G(d,p) | Geo. opt., interaction energy | [ | |
| 75 | β | fisetin | M06-2X | 6-31G(d,p) | gas, PCM | Geo. opt., interaction energy | [ |
| 76 | β | gallic acid | B97-D3 | 6-31G*, for GIAO: 6-311++g** | gas, solvent | Geo. opt., HOMO-LUMO, NBO, NMR | [ |
| 77 | β | gabapentin | B3LYP-D3 | 6- 31G(d) | vacuum, PCM | Geo. opt., interaction energy, NBO, HOMO-LUMO | [ |
| 78 | Β, γ | tropane alkaloids | B3LYP | 6-31+G(d,p) | PCM | Geo. opt., interaction energy, NMR | [ |
| 79 | β | coumarins | EDF2 | 6-311G(d,p) | PCM | Geo. opt. | [ |
| 80 | 2-HP-β | quercetin | B3LYP | 6-31G* | Geo. opt. | [ | |
| 81 | β | carvacrol, thymol | B3LYP | 6-31G, 6-31+G(d) | SMD | Geo. opt., interaction energy, NBO, HOMO-LUMO | [ |
| 82 | β | thymol | B3LYP, PBEPBE, CAM-B3LYP | 6-31G(d,p) | PCM | Geo. opt., interaction energy, UV–Vis | [ |
| 83 | β | carvacrol | B3LYP, M05-2X | 6-31G(d) | PCM | Geo. opt., HOMO-LUMO, NBO | [ |
|
| |||||||
| 84 | β | (−)-gallocatechin, (−)-catechin gallate, (−)-gallocatechin gallate | B3LYP | 6-31+G* for H, O and 4-31G for C | gas | Geo. opt., interaction and stabilization energy | [ |
| 85 | β | (−)-epigallocatechin, (−)-epigallocatechin gallate | B3PW91 | cc-pVDZ | gas | Geo. opt., interaction energy | [ |
| 86 | β | catechol derivatives: protocatechuic aldehyde, protocatechuic acid | B3LYP | 6-31+G* for H, O and 4-31G for C | gas (geo. opt.), implicit solvent (TD) | Geo. opt., interaction energy, TD | [ |
| 87 | β | oleuropein, hydroxytyrosol, tyrosol | n.i.p. | 6-31+G* for H, O and 4-31G for C | gas | Geo. opt., interaction energy, TD | [ |
| 88 | β | chlorogenic, caffeic, quinic acids | B3LYP | 6-31+G* for H, O and 4-31G for C | gas | Geo. opt., interaction energy, TD | [ |
|
| |||||||
| 89 | β | D- and L-penicillamine | B3LYP-D3 (geo. opt.); M062X-D3, xB97X-D, B3LYP-D3 (interaction energy) | 6-31G(d, p) (geo. opt.); G-311+G(d,p) (interaction energy) | water | Geo. opt., interaction energy | [ |
| 90 | metal-ion coupled β | D- and L-penicillamine | DFT, M062X | 6-31G(d,p) | vacuum | Geo. opt. | [ |
| 91 | β | R- and S-propranolol | B3LYP | 6-311+G(d,p) | vacuum | Geo. opt., vibrational spectra | [ |
| 92 | per-M β | D- and L-isoleucine | B3LYP (geo. opt.), wB97X-D (IR) | 6-31G*, 6-311G** | gas | Geo. opt., interaction energy, IR spectra, TD | [ |
| 93 | per-M β | D- and L-alanine | B3LYP, wB97X-D, M06-2X | 6-31G**, 6-311G** | Geo. opt., IR spectra | [ | |
| 94 | 2,3,6-TM-β | cis-(2S,4R) and -(2R,4S) ketoconazole | B3LYP | 6-311G(d,p) | gas (geo. opt.), PCM (SP) | Geo. opt., interaction energy | [ |
| 95 | 2-HP-β | abacavir enentiomers | PBE | 6-31G* | PCM | Geo. opt., interaction energy | [ |
Figure 3Comparison between the structures of the αCD complex with benzaldehyde. Top left: the best pose from molecular docking; top right: the best pose from molecular docking after optimization using DFT; bottom left: one of the poses obtained from molecular docking; bottom right: “bottom left” structure after optimization using DFT; middle one: experimental structure (CSDC ref. code: BOHWUQ). It should be noted that while the top left structure has energy lower than the bottom left by 3.4 kcal/mol, the top right structure has energy higher than the bottom right by 4.2 kcal/mol. Source: author’s archive.